Stem Cell Therapeutics (SCTPF) is certainly highly speculative. In fact, it's all the things I typically avoid in an investment--- it's an under-capitalized, Canadian penny stock with little data. The company is just beginning CD47 IND-enabling studies and will need to raise millions of dollars before it is able to bring a drug to the clinic. However, even with all those negatives, I decided to take a position.
CD47 could be a very important oncology target. In order for cancer to survive, it first has to find a way to evade the innate immune system, specifically, macrophages. Macrophages clear the body of dead/dying/damaged cells. Basically, macrophages have a signal regulating protein on their cell surface called SIRPa. Healthy cells express CD47 which binds to SIRPa and transmits a "do not eat me" signal to the macrophages. If a cell doesn't express sufficient CD47 then the macrophage engulfs the cell in a process known as phagocytosis. Some cancers - so far mainly hematological such as leukemia and lymphoma - have found a way to avoid phagocytosis by expressing CD47 on their own surfaces, in essence, tricking macrophages into leaving them alone. Both Stanford and Stem Cell Therapeutics (SCTPF) are developing an anti-CD47 fusion protein that prevents cancer cells from usurping this process.
If anyone's interested, here's the research I relied on to make my risk/reward assessment.
Market Data 
Markets 
AI
